Published in Adv Mater on June 25, 2010
Microstripes for transport and separation of magnetic particles. Biomicrofluidics (2012) 0.91
Isolation of cells for selective treatment and analysis using a magnetic microfluidic chip. Biomicrofluidics (2014) 0.89
On-Chip Magnetic Bead Manipulation and Detection Using a Magnetoresistive Sensor-Based Micro-Chip: Design Considerations and Experimental Characterization. Sensors (Basel) (2016) 0.78
Manipulation of Superparamagnetic Beads on Patterned Exchange-Bias Layer Systems for Biosensing Applications. Sensors (Basel) (2015) 0.77
Manipulation of small particles at solid liquid interface: light driven diffusioosmosis. Sci Rep (2016) 0.75
Tailoring magnetic anisotropy gradients by ion bombardment for domain wall positioning in magnetic multilayers with perpendicular anisotropy. Nanoscale Res Lett (2014) 0.75
Patterned time-orbiting potentials for the confinement and assembly of magnetic dipoles. Sci Rep (2013) 0.75
Exchange Bias Tuning for Magnetoresistive Sensors by Inclusion of Non-Magnetic Impurities. Sensors (Basel) (2016) 0.75
Effective pinning energy landscape perturbations for propagating magnetic domain walls. Sci Rep (2016) 0.75
Dynamic trajectory analysis of superparamagnetic beads driven by on-chip micromagnets. J Appl Phys (2015) 0.75
Transport and selective chaining of bidisperse particles in a travelling wave potential. Eur Phys J E Soft Matter (2016) 0.75
Synthetic amyloid-beta oligomers impair long-term memory independently of cellular prion protein. Proc Natl Acad Sci U S A (2010) 2.86
Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase I/II study. Lancet Oncol (2008) 2.70
Regulation of leukocyte recruitment by the long pentraxin PTX3. Nat Immunol (2010) 2.60
A recessive mutation in the APP gene with dominant-negative effect on amyloidogenesis. Science (2009) 2.30
Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ). Lancet Oncol (2008) 1.64
Cutting edge: scavenging of inflammatory CC chemokines by the promiscuous putatively silent chemokine receptor D6. J Immunol (2003) 1.52
Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma. Haematologica (2002) 1.47
Integrating post induction WT1 quantification and flow-cytometry results improves minimal residual disease stratification in acute myeloid leukemia. Leuk Res (2013) 1.42
Riluzole enhances the activity of glutamate transporters GLAST, GLT1 and EAAC1. Eur J Pharmacol (2007) 1.41
Interleukin-21 receptor (IL-21R) is up-regulated by CD40 triggering and mediates proapoptotic signals in chronic lymphocytic leukemia B cells. Blood (2006) 1.38
Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior. Blood (2009) 1.36
Neuropeptide Y gene therapy decreases chronic spontaneous seizures in a rat model of temporal lobe epilepsy. Brain (2008) 1.36
BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. Blood (2011) 1.35
Recombinant C1 inhibitor in brain ischemic injury. Ann Neurol (2009) 1.33
Interaction between human NK cells and bone marrow stromal cells induces NK cell triggering: role of NKp30 and NKG2D receptors. J Immunol (2005) 1.26
Electric control of the giant Rashba effect in bulk GeTe. Adv Mater (2012) 1.25
Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis. J Immunol (2011) 1.24
Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition. Blood (2012) 1.23
Vdelta1 T lymphocytes from B-CLL patients recognize ULBP3 expressed on leukemic B cells and up-regulated by trans-retinoic acid. Cancer Res (2004) 1.21
Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes. Clin Cancer Res (2009) 1.21
Differential recognition and scavenging of native and truncated macrophage-derived chemokine (macrophage-derived chemokine/CC chemokine ligand 22) by the D6 decoy receptor. J Immunol (2004) 1.19
An N-terminal fragment of the prion protein binds to amyloid-β oligomers and inhibits their neurotoxicity in vivo. J Biol Chem (2013) 1.18
The opposite effects of IL-15 and IL-21 on CLL B cells correlate with differential activation of the JAK/STAT and ERK1/2 pathways. Blood (2007) 1.12
Development of a proteolytically stable retro-inverso peptide inhibitor of beta-amyloid oligomerization as a potential novel treatment for Alzheimer's disease. Biochemistry (2010) 1.11
Designer magnetoplasmonics with nickel nanoferromagnets. Nano Lett (2011) 1.10
Gene therapy in epilepsy: the focus on NPY. Peptides (2006) 1.04
Misplaced NMDA receptors in epileptogenesis contribute to excitotoxicity. Neurobiol Dis (2011) 1.04
Antiepileptic effects of botulinum neurotoxin E. J Neurosci (2005) 1.03
Targeting mannose-binding lectin confers long-lasting protection with a surprisingly wide therapeutic window in cerebral ischemia. Circulation (2012) 1.03
Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia. Leuk Lymphoma (2011) 1.03
CTLA-4 is not restricted to the lymphoid cell lineage and can function as a target molecule for apoptosis induction of leukemic cells. Blood (2002) 1.02
The antidepressant mechanism of Hypericum perforatum. Life Sci (2004) 1.01
Plasmonic nickel nanoantennas. Small (2011) 1.01
Imatinib treatment induces CD5+ B lymphocytes and IgM natural antibodies with anti-leukemic reactivity in patients with chronic myelogenous leukemia. PLoS One (2011) 1.00
Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study. Ann Hematol (2006) 0.98
Consecutive regression of concurrent laryngeal and gastric MALT lymphoma after anti-Helicobacter pylori therapy. Gastroenterology (2003) 0.98
Predictors of response to rituximab in patients with neuropathy and anti-myelin associated glycoprotein immunoglobulin M. J Peripher Nerv Syst (2007) 0.97
The GTPase-activating protein RN-tre controls focal adhesion turnover and cell migration. Curr Biol (2013) 0.97
Specific recognition of biologically active amyloid-β oligomers by a new surface plasmon resonance-based immunoassay and an in vivo assay in Caenorhabditis elegans. J Biol Chem (2012) 0.97
Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. J Clin Oncol (2004) 0.97
High ERp5/ADAM10 expression in lymph node microenvironment and impaired NKG2D ligands recognition in Hodgkin lymphomas. Blood (2011) 0.97
Expansion of Vdelta1 T lymphocytes producing IL-4 in low-grade non-Hodgkin lymphomas expressing UL-16-binding proteins. Blood (2006) 0.96
Mutant PrP suppresses glutamatergic neurotransmission in cerebellar granule neurons by impairing membrane delivery of VGCC α(2)δ-1 Subunit. Neuron (2012) 0.96
Conformational plasticity of the Gerstmann-Sträussler-Scheinker disease peptide as indicated by its multiple aggregation pathways. J Mol Biol (2008) 0.95
New insights into the treatment of multiple myeloma with histone deacetylase inhibitors. Curr Pharm Des (2013) 0.95
WB4101-related compounds: new, subtype-selective alpha1-adrenoreceptor antagonists (or inverse agonists?). J Med Chem (2006) 0.95
Non-peptidic thrombospondin-1 mimics as fibroblast growth factor-2 inhibitors: an integrated strategy for the development of new antiangiogenic compounds. J Biol Chem (2010) 0.94
Intracellular NAD⁺ depletion enhances bortezomib-induced anti-myeloma activity. Blood (2013) 0.93
Curcumin-decorated nanoliposomes with very high affinity for amyloid-β1-42 peptide. Biomaterials (2010) 0.92
Versatile and efficient targeting using a single nanoparticulate platform: application to cancer and Alzheimer's disease. ACS Nano (2012) 0.91
WT1 overexpression at diagnosis may predict favorable outcome in patients with de novo non-M3 acute myeloid leukemia. Leuk Lymphoma (2011) 0.91
Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 yr treated with induction regimens including fludarabine: retrospective analysis of 224 cases. Eur J Haematol (2008) 0.91
Synergistic interactions between HDAC and sirtuin inhibitors in human leukemia cells. PLoS One (2011) 0.90
Kinase domain mutations of BCR-ABL identified at diagnosis before imatinib-based therapy are associated with progression in patients with high Sokal risk chronic phase chronic myeloid leukemia. Leuk Lymphoma (2010) 0.89
Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study. Amyloid (2012) 0.89
A T315I mutation in e19a2 BCR/ABL1 chronic myeloid leukemia responding to dasatinib. Leuk Res (2010) 0.89
Bendamustine with or without rituximab for the treatment of heavily pretreated non-Hodgkin's lymphoma patients : A multicenter retrospective study on behalf of the Italian Lymphoma Foundation (FIL). Ann Hematol (2012) 0.88
Donor lymphocyte infusions for the treatment of minimal residual disease in acute leukemia. Blood (2007) 0.88
Harnessing the liquid-phase exfoliation of graphene using aliphatic compounds: a supramolecular approach. Angew Chem Int Ed Engl (2014) 0.88
Use of surface plasmon resonance to study the elongation kinetics and the binding properties of the highly amyloidogenic Aβ(1-42) peptide, synthesized by depsi-peptide technique. Biosens Bioelectron (2010) 0.88
Appraisal of the role of angiotensin II and aldosterone in ventricular myocyte apoptosis in adult normotensive rat. J Mol Cell Cardiol (2002) 0.88
A modified protocol to prepare seed-free starting solutions of amyloid-β (Aβ)₁₋₄₀ and Aβ₁₋₄₂ from the corresponding depsipeptides. Anal Biochem (2010) 0.87
Resistance to CD95-mediated apoptosis of CD40-activated chronic lymphocytic leukemia B cells is not related to lack of DISC molecules expression. Hematol J (2004) 0.87
Affinity and activity profiling of unichiral 8-substituted 1,4-benzodioxane analogues of WB4101 reveals a potent and selective α1B-adrenoceptor antagonist. Eur J Med Chem (2012) 0.87
Intracellular NAD(+) depletion induces autophagic death in multiple myeloma cells. Autophagy (2013) 0.87
PEGylated nanoparticles bind to and alter amyloid-beta peptide conformation: toward engineering of functional nanomedicines for Alzheimer's disease. ACS Nano (2012) 0.86
Novel approaches for studying amyloidogenic peptides/proteins. Curr Opin Pharmacol (2013) 0.86
Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia patients. Cancer Chemother Pharmacol (2014) 0.86
Immunopurification of pathological prion protein aggregates. PLoS One (2009) 0.86
Tuning the magneto-optical response of nanosize ferromagnetic Ni disks using the phase of localized plasmons. Phys Rev Lett (2013) 0.86
Aminobisphosphonates prevent the inhibitory effects exerted by lymph node stromal cells on anti-tumor Vδ 2 T lymphocytes in non-Hodgkin lymphomas. Haematologica (2013) 0.85
Nanosized corners for trapping and detecting magnetic nanoparticles. Nanotechnology (2009) 0.85
APO866 activity in hematologic malignancies: a preclinical in vitro study. Blood (2009) 0.85
Flexible and stretchable polymers with embedded magnetic nanostructures. Adv Mater (2012) 0.85
Sign control of magnetoresistance through chemically engineered interfaces. Adv Mater (2014) 0.85
Good gene, bad gene: new APP variant may be both. Prog Neurobiol (2012) 0.84
Polarizability and magnetoplasmonic properties of magnetic general nanoellipsoids. Opt Express (2013) 0.84
Chromosome 2p gain in monoclonal B-cell lymphocytosis and in early stage chronic lymphocytic leukemia. Am J Hematol (2012) 0.84
An electrospray ionization source for integration with microfluidics. Anal Chem (2002) 0.84
CD40 triggering enhances fludarabine-induced apoptosis of chronic lymphocytic leukemia B-cells through autocrine release of tumor necrosis factor-alpha and interferon-gama and tumor necrosis factor receptor-I-II upregulation. Haematologica (2003) 0.84
Selective nanovector mediated treatment of activated proinflammatory microglia/macrophages in spinal cord injury. ACS Nano (2013) 0.84
Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemias. Am J Hematol (2015) 0.83
Prospective phase II Study on 5-days azacitidine for treatment of symptomatic and/or erythropoietin unresponsive patients with low/INT-1-risk myelodysplastic syndromes. Clin Cancer Res (2013) 0.83
Applications of surface plasmon resonance (SPR) for the characterization of nanoparticles developed for biomedical purposes. Sensors (Basel) (2012) 0.82
Large room-temperature electroresistance in dual-modulated ferroelectric tunnel barriers. Adv Mater (2015) 0.81
CTLA-4 +49A>G polymorphism of recipients of HLA-matched sibling allogeneic stem cell transplantation is associated with survival and relapse incidence. Ann Hematol (2009) 0.81
CTLA-4 expressed by chemoresistant, as well as untreated, myeloid leukaemia cells can be targeted with ligands to induce apoptosis. Br J Haematol (2007) 0.81
The binding affinity of anti-Aβ1-42 MAb-decorated nanoliposomes to Aβ1-42 peptides in vitro and to amyloid deposits in post-mortem tissue. Biomaterials (2011) 0.81
Tracking molecular relapse of chronic myeloid leukemia by measuring Hedgehog signaling status. Leuk Lymphoma (2012) 0.81
Engineered fabrication of ordered arrays of Au-NiO-Au nanowires. Nanotechnology (2013) 0.80
Rituximab efficacy in CIDP associated with idiopathic thrombocytopenic purpura. Muscle Nerve (2008) 0.80